Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

InteRNA Technologies Receives Notice of Allowance for miRNA Sequences of its Lead Pre-Clinical Product

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.

InteRNA Technologies B.V. announces that the United States Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on a patent application covering miRNA sequences, identified through deep sequencing of several different mouse, monkey and human samples, including different tumor samples. The allowable product claims protect miRNA-3157, homologues, precursors and mimics thereof. In a second pending patent application, miRNA-3157, homologues, precursors and mimics thereof are claimed as a therapy against melanoma. A mimic of miRNA-3157 is entering preclinical development and represents InteRNA's lead product in its B-Raf/melanoma program.

"This issuance of the USPTO confirms our unique approach to identification and validation of miRNAs as drug targets and further development towards the clinic", said Roel Schaapveld, CEO of InteRNA Technologies. "It further subscribes our patent strategy and greatly strengthens our intellectual property position on miRNA drug candidates."

The latest data on miRNA-3157 as drug candidate for the treatment of human melanoma will be presented at the Society for Melanoma Research 2012 Congress, November 8-11 in Hollywood, CA, USA.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InteRNA Technologies Secures Final Extension Series A Financing
Company has announced Hans Schikan as new chairman of its Supervisory Board.
Saturday, October 31, 2015
InteRNA Technologies, UCB and University of Bonn to Collaborate
Agreement on the role of microRNAs in neurodegenerative disease.
Friday, January 10, 2014
MiRacle Consortium Receives a € 1.2 Million FP7 Grant from the European Union
Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer – acronym: MiRacle.
Monday, November 04, 2013
InteRNA Technologies Announces Closing of Equity Financing Round
Company secures additional equity financing to progress lead program for melanoma treatment.
Friday, September 06, 2013
InteRNA Technologies Receives Notice of Allowance from USPTO
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program.
Tuesday, October 16, 2012
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Robotic Cleaning Technique Could Automate Neuroscience Research
New robotic cleaning technique allows pipettes used in patch-clamping to be re-used up to 11 or more times.
Startup Seeks More Precise Prostate Cancer Screening
Gregor Diagnostics aims to bring a non-invasive prostate cancer screening test to the market.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos